Promomed Group begins joint work with the Skolkovo Foundation
At the XXV St. Petersburg International Economic Forum, a cooperation agreement was signed between Promomed Group, Biokhimik JSC and the Skolkovo Foundation with the aim of starting joint work in the development of biotechnological drugs and new dosage forms, improving methods of synthesis of pharmaceutical substances, conducting and coordinating a full range of preclinical and clinical studies and the potential establishment of a modern research center at the site of the regional operator of the Skolkovo Foundation in the Republic of Mordovia*.
Petr Bely, Chairman of the Board of Directors of Promomed Group, comments on the decision to cooperate in the field of development and research with the Development Fund of the Center for the Development and Commercialization of New Technologies: «A new era in medicine has arrived: biotechnologies, RNA therapy, domestic substances of the highest quality are the response to the challenges of today. We will take up these challenges together with the leader in innovations, the Skolkovo Foundation. We see great prospects in joint work on the modeling of candidate molecules for medicinal products, the development of methods for the synthesis of pharmaceutical substances; optimization and improvement of production processes of APIs and finished dosage forms and in other areas. The critical challenges of medicine, which Promomed traditionally works on, require the consolidation of the best forces.»
After the signing ceremony, Dmitry Zemskov, the Executive Director of Biokhimik JSC (member of Promomed Group), commented that this agreement is not quite typical, it is filled with specifics. «This reflects our most determined intentions in achieving our goals. We are already discussing in detail with our partners from Skolkovo the possibilities for creating a research center based on the regional operator of the Skolkovo Foundation in the Republic of Mordovia, and we are also considering the possibility of receiving resident status by the Biokhimik JSC.»
«I think we will see the results of this cooperation soon and patients will be offered affordable quality drugs,» Zemskovsaid.
Igor Drozdov, Chairman of the Board of the Skolkovo Foundation: «One of the priorities of the state program «Development of the pharmaceutical and medical industry» is import independence. Skolkovo aims at this task within the framework of cooperation with leading domestic pharmaceutical companies. We are confident that the partner center based on our regional operator in Mordovia will be very useful in the creation of medicines for the population of our country.»
The creation of a Research Partner Center (RPI) is of great strategic importance for the implementation of the state program «Development of the pharmaceutical and medical industry», which must solve one of the most important tasks – the independence of Russia from imports. A cluster of this kind will make it possible to conduct and coordinate a full range of preclinical and clinical studies to bring promising developments to the stage of a product ready for commercialization.
* R&D Center of Technopark-Mordovia
